# A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

> **NCT04931342** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 176 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Ipatasertib
- **DRUG:** Cobimetinib
- **DRUG:** Trastuzumab Emtansine
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Giredestrant
- **DRUG:** Abemaciclib
- **DRUG:** Inavolisib
- **DRUG:** Palbociclib
- **DRUG:** Letrozole
- **DRUG:** Olaparib
- **DRUG:** Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
- **DRUG:** Cyclophosphamide
- **DRUG:** Inavolisib

## Key facts

- **NCT ID:** NCT04931342
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-07
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-05-30
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04931342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04931342, "A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04931342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*